A paper titled Interpretation of Clinical Research Result of Danoprevir-based Antiviral Regimen in the Treatment of Chronic Hepatitis C was published in the latest Chin J Infect Dis (October 2018, Vol. 36, No. 10). The paper is co-authored by Prof. Jianrong Huang from First Affiliated Hospital of Medical College of Zhejiang University and Prof. Wenhong Zhang from Huashan Hospital Affiliated to Fudan University,
Chin J Infect Dis is the leading journal in China and both Prof. Huang and Prof. Zhang are authoritative key opinion leaders in infectious diseases in China. The paper summarizes the clinical trials and results of Danoprevir-based antiviral regimens in the treatment of chronic hepatitis C. The key messages, interpretations of the study and the original paper are enclosed for your reference.
1. Danoprevir is a new generation and pan-genotypic protease inhibitor, danoprevir has potent anti-viral activity against HCV protease derived from HCV genotypes 1 through 6.
2. Treatment eligible patients of Danoprevir include treatment naïve HCV genotype 1 and 4 patients with non-cirrhosis and compensated cirrhosis status, high risk liver cancer population, co-infection of hepatitis B with hepatitis C, and renal insufficiency patient population.
3. The Danoprevir-based antiviral regimens used in the study includes triple therapy (Danoprevir in combination with PEGylated interferon and ribavirin), and all-oral interferon-free therapy (Danoprevir in combination with NS5A inhibitor).
4. The clinical research results showed that Danoprevir is safe and well tolerated.
5. As the first innovative DAA developed by a domestic company in China, Danoprevir is a cost effective HCV treatment and plays an important role in prevention and control of HCV in China and worldwide.
Notes: Prescription information is subject to instructions.
Original (in Chinese only)：